0.41%| Prev Close: | 3,215.50 |
|---|---|
| Open: | 3,211.00 |
| Bid: | 3,165.00 |
| Ask: | 3,300.00 |
| 1y Target Est: | 51.54 |
| Beta: | N/A |
| Next Earnings Date: | N/A |
| Day's Range: | 3,191.00 - 3,220.00 |
|---|---|
| 52wk Range: | 442.87 - 3,544.50 |
| Volume: | 1,435,558 |
| Avg Vol (3m): | 1,738,160 |
| Market Cap: | 40.21B |
| P/E (ttm): | 819.47 |
| EPS (ttm): | 3.92 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in GBp.
Headlines
- Merck to slash annual costs by $2.5 billion, cut 8,500 jobsReuters(Tue 2:08PM EDT)
- Merck to slash annual costs by $2.5 bln, cut 8,500 jobsReuters(Tue 2:06PM EDT)
- Lundbeck, Takeda Win U.S. Approval for Depression Therapyat Bloomberg(Mon, Sep 30)
- 3 More FTSE 100 Shares To Avoid Market Madness: AstraZeneca plc, Severn Trent Plc and Smith & Nephew plcat Motley Fool(Mon, Sep 30)
- AstraZeneca CEO gets two cheers after first year in jobReuters(Mon, Sep 30)
- The Surprising Sell Case For AstraZeneca plcat Motley Fool(Thu, Sep 26)
- 3 Reasons Why I’m Bullish On AstraZeneca plcat Motley Fool(Wed, Sep 25)
- Why AstraZeneca plc Is A Great Share For Novice Investorsat Motley Fool(Mon, Sep 23)
- Ranbaxy Ratings Cut After FDA Restricts Imports to U.S.at Bloomberg(Tue, Sep 17)
- [$$] Drugs for Inherited Cancers Get Fresh Pushat The Wall Street Journal(Mon, Sep 16)
- 3 Worrying Reasons Why AstraZeneca plc Is Ready To Plummetat Motley Fool(Thu, Sep 12)
- 3 Numbers To Consider Before Buying AstraZeneca plcat Motley Fool(Thu, Sep 12)
- AstraZeneca pays $50 million for rights to Merck cancer drugReuters(Wed, Sep 11)
- Reasons To Buy, Hold Or Sell AstraZeneca plcat Motley Fool(Wed, Sep 11)
- Why AstraZeneca Plc Has Underperformed The FTSE 100 Over The Past Yearat Motley Fool(Tue, Sep 10)
Press Releases
- New Antibiotic Treatment for Patients With Serious Skin Infections Becomes Available in WalesPR Newswire(Thu, Aug 1)
- AstraZeneca: MedImmune, AstraZeneca’s Biologics Arm, and NGM Biopharmaceuticals Announce Agreement to Discover and Develop Therapies for Diabetes and ObesityBusiness Wire(Mon, Jun 17)
- Adult Patients in England and Wales to Gain Access to First-in-Class Type 2 Diabetes TreatmentPR Newswire(Wed, May 29)
Reports
- Thomson Reuters Stock Report - ASTRAZENECA PLC (AZN-LN)Thomson Reuters Stock Report(Oct 1)
- AstraZeneca PLC: Business description, financial summary, 3yr and interim financials,...Reuters Investment Profile(Sep 28)
- AstraZeneca PLC (AZN) - Pharmaceuticals & Healthcare - Deals and Alliances ProfileGlobalData(Sep 25)